Vimarsana
Biggest News Aggregation in the World

Page 46 - Main Board News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Main Board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Main Board Today - Breaking & Trending Today

Investegate | Company Announcement - Vimarsana News

Investegate | Company Announcement

Investegate announcements from Result of AGM

Investegate | Company Announcement - Vimarsana News

Investegate | Company Announcement

Investegate announcements from UPDATE ON THE PRE-SALE OFDAMBOVITA CENTER PROJECT

RANKINGS: ALB Asia Singapore Rising Stars 2023 | Asian Legal Business - Vimarsana News

RANKINGS: ALB Asia Singapore Rising Stars 2023 | Asian Legal Business

Asian Legal Business releases its second annual ranking of the emerging legal talents in Singapore. The list includes lawyers who have demonstrated exceptional potential and received praise from their clients. The list is arranged alphabetically, and some lawyers have been featured in profiles.v

Garden Stage Ltd. (GSIW) to Raise $9 Million in IPO - Vimarsana News

Garden Stage Ltd. (GSIW) to Raise $9 Million in IPO

Garden Stage Ltd. (GSIW) expects to raise $9 million in an initial public offering (IPO) on Friday, December 1st, IPO Scoop reports. The company will be issuing 2,000,000 shares at a price of $4.00-$5.00 per share. In the last 12 months, Garden Stage Ltd. generated $3.3 million in revenue and had a net loss of […]

Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients - Vimarsana News

Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients

HONG KONG, Nov. 27, 2023 /PRNewswire/ -- Akeso has announced that the AK104-303 Phase III trial, which investigated cadonilimab combined with platinum-based chemotherapy +/- bevacizumab, has met...